ACROFAN

Wednesday, July 6, 2022

- General
- Aerospace/Defense
- Logistics/Transport
- Construction/Build
- Energy
- Machine
- Material
- Bio/Medical
- Food
- Beauty
- Fashion
- Infant
- General
- Policy
- Finance
- Stock
- RealEstate
- Startup
- Franchise
- Retail
- Overseas
- Computer
- Mobile
- Device
- Component
- Enterprise
- Carrier
- Internet
- Security
- Review
- Information
- PC
- Console
- Mobile
- eSports
- Development
- Review
- Information
- Automobile
- Automotive
- After Market
- Car Culture
- Traffic
- Review
- Information
- Broadcast
- Entertainment
- Movie
- Music
- K-Wave
- Review
- Information
- General
- Assembly
- Court
- Government
- Education
- Science
- Environment
- Employment
- Welfare
- Media
- Social Contribution
- Opinion
- General
- Travel
- Leisure
- Restaurants
- Festival
- Event
- Local Area
- International
- Book
- Religion
- Health
- Sports

Industry	Economy	TECH	GAME	AUTO	MEDIA	Society	Comfort	Theme	Photo	Media	Publish
General Aerospace/Defense Logistics/Transport Construction/Build Energy Machine Material Bio/Medical Food Beauty Fashion Infant	General Policy Finance Stock RealEstate Startup Franchise Retail Overseas	Computer Mobile Device Component Enterprise Carrier Internet Security Review Information	PC Console Mobile eSports Development Review Information	Automobile Automotive After Market Car Culture Traffic Review Information	Broadcast Entertainment Movie Music K-Wave Review Information	General Assembly Court Government Education Science Environment Employment Welfare Media Social Contribution Opinion	General Travel Leisure Restaurants Festival Event Local Area International Book Religion Health Sports	Theme	Photo	Media	Publish

Adyen provides omnichannel payments services to UNIQLO

Adyen financial technology platform supports Fast Retailing move to strengthen omnichannel payments. AMSTERDAM, July 6, 2022 /PRNewswire/ -- Adyen (AMS: ADYEN), the financial technology platform of choice for leading companies, has been ch..

Wednesday, July 6, 2022, 9:00 am

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascleti..

Wednesday, July 6, 2022, 8:10 am

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022